This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cassava Sciences’s 8K filing here.
About Cassava Sciences
Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.
Featured Stories
- Five stocks we like better than Cassava Sciences
- What Investors Need to Know About Upcoming IPOs
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- What Are Trending Stocks? Trending Stocks Explained
- Discover the 3 Best Performing Stocks That Went Public in 2024
- How to Use the MarketBeat Dividend Calculator
- 3 Strategic ETFs for Bearish Investors Post-Election
